Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-guided coumarin dosing: where are we now and where do we need to go next?

Expert opinion on drug metabolism & toxicology - 1 Apr 2015

Baranova Ekaterina V, Verhoef Talitha I, Asselbergs Folkert W, de Boer Anthonius, Maitland-van der Zee Anke-Hilse

Abstract excerpt

INTRODUCTION: A large proportion of the coumarin dose variability is explained by environmental factors and by common genetic variants in the VKORC1 and CYP2C9 genes. Genotype-guided coumarin dosing has been proposed for a more accurate prediction of the coumarin dose in order to reduce the incidence of coumarin-related complications. AREAS COVERED: This review discusses the current state of coumarin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coumarins

Share to Cytochrome P-450 CYP2C9

Share to Dose-Response Relationship, Drug

Share to Ethnicity

Share to Pharmacogenetics

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 25595525
DOI: 10.1517/17425255.2015.1004053

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-guided coumarin dosing: where are we now and where do we need to go next?PMID 25595525Read ↗

Pharmacogenetics-based coumarin therapy.Semantic proximity Read ↗

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.Semantic proximity Read ↗

The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?Semantic proximity Read ↗

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.Semantic proximity Read ↗

Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Semantic proximity Read ↗

Pharmacogenomics of anticoagulants: steps toward personal dosageSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Pharmacogenetics and coumarin dosing--recalibrating expectations.Semantic proximity Read ↗

Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.Semantic proximity Read ↗

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Semantic proximity Read ↗

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.Semantic proximity Read ↗

Patients benefit from genetics-guided coumarin anticoagulant therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.